ICAM-1-suPAR-CD11b轴是转移性三阴性乳腺癌的新型治疗标
Dong Li1, Hami Hemati1, Younhee Park1
1Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.
Cancers
|June 22, 2023
概括
中性细胞-癌细胞群增强转移. 阻止ICAM-1-suPAR-CD11b通路通过防止中性粒细胞与循环瘤细胞 (CTC) 结合,抑制三阴性乳腺癌 (TNBC) 转移.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 循环瘤细胞 (CTC) 集群,特别是涉及中性粒细胞的异型集群,与转移的增加和较差的患者结局有关.
- 驱动中性粒细胞循环瘤细胞 (CTC) 相互作用的精确分子机制在很大程度上是未知的.
- 三阴性乳腺癌 (TNBC) 表现出侵略性行为,转移是死亡的主要原因.
研究的目的:
- 阐明中性粒细胞结合TNBC中CTC的机制.
- 研究细胞间粘附分子-1 (ICAM-1) 和CD11b在中性粒细胞-CTC相互作用中的作用.
- 为了确定抑制TNBC转移的潜在治疗点.
主要方法:
- 研究了TNBC细胞上的细胞间粘附分子-1 (ICAM-1) 和中性粒细胞上的CD11b,以调解瘤细胞与中性粒细胞的结合.
- 评估了CD11b缺乏对瘤细胞中性粒细胞结合和TNBC转移的影响.
- 研究了CD11b在中性粒细胞过氧化 (H2O2) 生产中的作用.
- 研究了ICAM-1在促进TNBC细胞分泌的作用及其对中性粒细胞的化学吸引作用.
- 在ICAM-1+ TNBC细胞中利用了尿素酶等离子体激活器受体 (uPAR) 的淘汰作用.
- 进行生物信息学分析,以将UPAR表达与中性粒细胞透和患者存活率相关联.
主要成果:
- 在TNBC细胞上的ICAM-1和中性粒细胞上的CD11b被确定为瘤细胞与中性粒细胞结合的关键媒介.
- 缺少CD11b显著降低了瘤细胞与中性粒细胞的结合和TNBC转移.
- 发现CD11b调解了中性粒细胞的过氧化 (H2O2) 生产.
- 在TNBC细胞中的ICAM-1表达促进了suPAR分泌,作为中性粒细胞化学吸引剂.
- 在ICAM-1+ TNBC细胞中抑制UPAR导致肺中性粒细胞透和转移的减少.
- 生物信息学分析揭示了TNBC中高UPAR表达,与中性粒细胞透呈正相关,与患者生存呈负相关.
结论:
- ICAM-1-suPAR-CD11b轴是一个关键通路,促进中性粒细胞与CTC结合,并促进TNBC转移.
- 准这一轴是抑制三阴性乳腺癌转移的有希望的治疗策略.
- 了解这些细胞相互作用为癌症进展和潜在的治疗干预提供了新的见解.
相关概念视频
Immunoglobulin-like Cell Adhesion Molecules
3.3K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.3K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


